Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3700028 | 0.89 | KMT2A (0.44) | TP53KMT2AALDH1A1MEN1GAA | |
| SCHEMBL16257497 | 0.87 | TP53 (0.44) | TP53KMT2AALDH1A1MEN1GAA | |
| SCHEMBL3695927 | 0.87 | TP53 (0.55) | TP53KMT2AALDH1A1MEN1GAA | |
| SCHEMBL4125657 | 0.86 | MAPT (0.53) | TP53KMT2AALDH1A1MEN1GAA | |
| SCHEMBL3695660 | 0.85 | TP53 (0.51) | TP53KMT2AALDH1A1MEN1GAA | |
| SCHEMBL3699441 | 0.85 | MAPT (0.48) | TP53KMT2AALDH1A1MEN1GAA | |
| SCHEMBL3695444 | 0.85 | TP53 (0.51) | TP53KMT2AALDH1A1MEN1GAA | |
| SCHEMBL20077903 | 0.84 | KMT2A (0.48) | TP53KMT2AALDH1A1MEN1GAA | |
| SCHEMBL2838912 | 0.84 | PDE4B (0.53) | TP53KMT2AALDH1A1MEN1GAA | |
| SCHEMBL3701832 | 0.83 | TP53 (0.46) | TP53KMT2AALDH1A1MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2412713-B1 | PYRAZOLE COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-11-30 | — | — | EP | disclosed |
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-8895588-B2 | Pyrazole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895588-B2 | Pyrazole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20120095057-A1 | PYRAZOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120095057-A1 | PYRAZOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-2412713-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2012-02-01 | — | — | EP | disclosed |
| EP-2190822-A2 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009041705-A9 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2009-08-13 | — | — | WO | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2009041705-A2 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | TP53 4668/4885KMT2A 4776/4885ALDH1A1 1497/4885 |
| US-20120095057-A1 | PYRAZOLE COMPOUND | CEL, HRH2, GIPR | TP53 4548/4885KMT2A 4584/4885ALDH1A1 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.